Results 41 to 50 of about 2,663 (168)

Sleep Disturbances and Phenoconversion in Patients with REM Sleep Behavior Disorder [PDF]

open access: yesJournal of Clinical Medicine, 2021
Objective: We aimed to investigate relationships between sleep disturbances and phenoconversion to neurodegenerative diseases in patients with REM sleep behavior disorder (RBD). Method: Using a comprehensive sleep database in a university-affiliated hospital between December 2014 and March 2021, we reviewed the data of 226 patients with RBD (182 ...
Hyunjin Jo   +4 more
openaire   +2 more sources

Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure [PDF]

open access: yesEuropean Archives of Psychiatry and Clinical Neuroscience, 2019
The efficacy of aripiprazole therapy and the risk of adverse reactions are influenced by substantial inter-individual variability in aripiprazole metabolizing capacity. In vitro studies assigned the potential role in aripiprazole metabolism to CYP2D6 and CYP3A enzymes; therefore, the association between the steady-state aripiprazole plasma ...
Ádám Kiss   +9 more
openaire   +3 more sources

Table_1_Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.DOCX

open access: yes, 2021
Introduction: Polypharmacy and genetic variants that strongly influence medication response (pharmacogenomics, PGx) are two well-described risk factors for adverse drug reactions.
Carl M. J. Kirkpatrick (11294292)   +4 more
core   +1 more source

CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting

open access: yesFrontiers in Pharmacology, 2021
Pharmacokinetic variability is a major source of differences in drug response and can be due to genetic variants and/or drug-drug interactions. Cytochromes P450 are among the most studied enzymes from a pharmacokinetic point of view.
Kuntheavy Ing Lorenzini   +6 more
doaj   +1 more source

Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall

open access: yesMedicina, 2023
Pharmacotherapy for major depressive disorder (MDD) typically consists of trial-and-error and clinician preference approaches, where patients often fail one or more antidepressants before finding an optimal regimen.
Joshua Russell   +6 more
doaj   +1 more source

Cardiosomal microRNAs Are Essential in Post-Infarction Myofibroblast Phenoconversion [PDF]

open access: yesInternational Journal of Molecular Sciences, 2019
The inclusion of microRNAs (miRNAs) in extracellular microvesicles/exosomes (named cardiosomes when deriving from cardiomyocytes) allows their active transportation and ensures cell-cell communication. We hypothesize that cardiosomal miRNAs play a pivotal role in the activation of myofibroblasts following ischemic injury.
Morelli Marco Bruno   +4 more
openaire   +5 more sources

Characterization of Depressive and Anxiety Symptoms in Idiopathic REM Sleep Behavior Disorder

open access: yesJournal of Parkinson’s Disease, 2021
Background: Depression and anxiety are common in synucleinopathies and often present during prodromal stages, including idiopathic/isolated REM sleep behavior disorder (iRBD).
Lucy Honeycutt   +5 more
doaj   +1 more source

Phenoconversion: Drug-Drug-Gene Interactions [PDF]

open access: yes, 2019
Based on the extensive, poor, intermediate and ultrarapid phenotypes of patients, inferences may be made relative to drug metabolism, ultimately leading to changes in therapeutic drug choice or dosing.
Kulp, Molly   +4 more
core   +1 more source

Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model [PDF]

open access: yesIranian Journal of Basic Medical Sciences, 2020
Objective(s): Alteration in drug metabolism is very likely in diabetes mellitus. This study assessed changes in CYP2C19 enzymatic activity in the liver using omeprazole as a probe in the animal model of type II diabetes (T2DM) before and after treatment ...
Navid Neyshaburinezhad   +4 more
doaj   +1 more source

Dasatinib-induced nephrotic syndrome: a case of phenoconversion?

open access: yesCroatian Medical Journal, 2019
We present the case of a 33-year-old chronic myeloid leukemia (CML) female patient, in whom the occurrence of nephrotic syndrome, during the treatment with tyrosine kinase activity inhibitors (TKIs), was potentially influenced by transient phenoconversion.
Mandac Rogulj, Inga   +6 more
openaire   +6 more sources

Home - About - Disclaimer - Privacy